Loading...

Accuray Incorporated

0H8I.L•LSE
Healthcare
Medical - Equipment & Services
£1.38
£-0.02(-1.44%)

Accuray Incorporated (0H8I.L) Stock Overview

Explore Accuray Incorporated’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.6/100

Key Financials

Market Cap148.3M
P/E Ratio-33.39
EPS (TTM)$-0.14
ROE-0.10%
Fundamental Analysis

AI Price Forecasts

1 Week$1.56
1 Month$1.09
3 Months$1.45
1 Year Target$1.80

0H8I.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Accuray Incorporated (0H8I.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 59.47, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.80.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -33.39 and a market capitalization of 148.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

59.47RSI (14)
0.00MACD
15.18ADX
Revenue Growth
-0.24%
↓ 0.24%
Profit Growth
£-0.04
↓ 67.51%
EPS Growth
£-0.04
↓ 63.60%
Operating Margin
1.06%
↓ 78.84%
ROE
-9.75%
↓ 67.51%
Dividend Yield
0.00%
Analyst Recommendations data is not available for 0H8I.LAnalyst Recommendations details for 0H8I.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney. The company also provides the TomoTherapy System, including the Radixact System, which consists of an integrated radiation therapy system designed for the treatment of a range of cancer types. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.

CEO

Suzanne Winter

Employees

987

Headquarters

1310 Chesapeake Terrace, Madison, CA

Founded

2018

Frequently Asked Questions

;